Welcome to our dedicated page for ExcelFin Acquisition news (Ticker: XFIN), a resource for investors and traders seeking the latest updates and insights on ExcelFin Acquisition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ExcelFin Acquisition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ExcelFin Acquisition's position in the market.
Norwegian Cruise Line (NYSE:NCLH) opened sales for Norwegian Aura, its largest ship: ~1,130 feet, 169,000 gross tons and 3,840 guests at double occupancy. Debut voyages begin in Europe May 21, 2027, with Miami homeporting from June 2027 and Caribbean seven-day itineraries visiting Harvest Caye or Great Stirrup Cay. Key features include the multi-deck open-air Ocean Heights activities complex, five waterslides, expanded Ocean Boulevard, the largest pool deck in the fleet, and The Haven with 30% more suites.
Baird Medical, a leading microwave ablation (MWA) medical device developer in China with recent expansion into the U.S. market, and ExcelFin Acquisition Corp (NASDAQ: XFIN) have completed their business combination. The resulting company, Baird Medical Investment Holdings (PubCo), will begin trading on Nasdaq under the symbols 'BDMD' and 'BDMDW' on October 2, 2024.
At ExcelFin's special meeting, 99.9% of votes cast approved the business combination. Upon completion, founders of Baird Medical and Grand Fortune Capital, subscribed to a $4,900,000 Convertible Preferred investment in the Company. The transaction involved various advisors, including Dechert LLP, Allen Overy Shearman Sterling US LLP, and Cohen & Company Capital Markets, among others.
Baird Medical, a leading microwave ablation (MWA) medical device developer in China, and ExcelFin Acquisition Corp (NASDAQ: XFIN) have announced the effectiveness of Baird Medical Investment Holdings 's registration statement on Form F-4. This marks a important step towards Baird Medical becoming a publicly-traded company on Nasdaq through their proposed business combination.
ExcelFin has scheduled a Special Meeting of Stockholders for September 26, 2024, to approve the business combination. The transaction is expected to close shortly after stockholder approval and satisfaction of other customary closing conditions. Stockholders are urged to review the proxy statement/prospectus and other relevant documents filed with the SEC for important information about the proposed transaction.
Summary not available.
Summary not available.
Summary not available.
ExcelFin Acquisition Corp. (Nasdaq: XFIN) announced that as of December 13, 2021, holders of its initial public offering units can separately trade Class A common stock and warrants. The Class A common stock will trade under the ticker XFIN, while the warrants will trade under XFINW. Each unit consists of one share of Class A common stock and one-half of a redeemable warrant, with whole warrants exercisable at $11.50 per share. Units not separated will continue trading as XFINU.
ExcelFin Acquisition Corp. (NASDAQ: XFIN) has priced its initial public offering (IPO) at